EP
RARE icon

Edgestream Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Edgestream Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-99,873
Closed -$2.3M – 1067
2025
Q4 		$2.3M Buy
+99,873
New +$3.28M 0.06% 495
2023
Q2 		– Sell
-6,666
Closed -$267K – 879
2023
Q1 		$267K Buy
+6,666
New +$286K 0.03% 488
2022
Q4 		– Sell
-17,111
Closed -$709K – 615
2022
Q3 		$709K Buy
+17,111
New +$879K 0.05% 314

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Edgestream Partners's RARE Position: Q1 2026 in Review

Edgestream Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 99,873 shares — an estimated $2.3M sold.

Edgestream Partners first reported a position in RARE in Q3 2022 and held it in 3 quarters. The position peaked at $2.3M in Q4 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Edgestream Partners reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Edgestream Partners sold 99,873 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $2.3M.
  • Edgestream Partners first reported a position in Ultragenyx Pharmaceutical in Q3 2022 and held it in 3 quarters.
  • Edgestream Partners's Ultragenyx Pharmaceutical position peaked at $2.3M in Q4 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Edgestream Partners's 13F filing for Q1 2026, filed 18 May 2026.